Peptide record

TPDB09860

Buforin IIb Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09860
Buforin IIb
Antibacterial Anticancer Antifungal Antiparasitic Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab Antifungipept CAFPdb CPPsite3.0 HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 21-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
RAGLQFPVGRLLRRLLRRLLR
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C115H207N43O23
NDCEHIKMSTWY
RL
2560.18
13.18
7
0
10
+7
3.09
-0.095
148.57
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
0
0.00
1
Residue Composition
number
1
A
7
R
0
N
0
D
0
C
0
E
1
Q
2
G
0
H
0
I
7
L
0
K
0
M
1
F
1
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 1 R: 7 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 2 H: 0 I: 0 L: 7 K: 0 M: 0 F: 1 P: 1 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
21 reviewed residue count
C115H207N43O23 sequence-only estimate (linear, free termini)
2560.18 sequence-only estimate (linear, free termini)
13.18 sequence-only estimate (linear, free termini)
+7 sequence-only estimate (linear, free termini)
3.09 sequence-only estimate (linear, free termini)
-0.095 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Linear Activity
Free Activity
Antibacterial Activity
histone H2A Activity
Evidence Records 61 records
Evidence 1 Activity

Activity

IC50
IC50=14.7 µg/ml
Anticancer
14.7 µg/mL

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=11.3 µg/ml
Anticancer
11.3 µg/mL

Target

Leukemia Cancer
HL-60
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 3 Activity

Activity

IC50
IC50=8.2 µg/ml
Anticancer
8.2 µg/mL

Target

Leukemia Cancer
K-562
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 4 Activity

Activity

IC50
IC50=17 µg/ml
Anticancer
17 µg/mL

Target

Leukemia Cancer
MOLT-4
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 5 Activity

Activity

IC50
IC50=10.5 µg/ml
Anticancer
10.5 µg/mL

Target

Leukemia Cancer
RPMI-8226
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 6 Activity

Activity

IC50
IC50=20.2 µg/ml
Anticancer
20.2 µg/mL

Target

Leukemia Cancer
SR
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 7 Activity

Activity

IC50
IC50=15.1 µg/ml
Anticancer
15.1 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 8 Activity

Activity

IC50
IC50=11.5 µg/ml
Anticancer
11.5 µg/mL

Target

Breast Cancer
NCI/ADR-RES
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 9 Activity

Activity

IC50
IC50=11.3 µg/ml
Anticancer
11.3 µg/mL

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 10 Activity

Activity

IC50
IC50=11.7 µg/ml
Anticancer
11.7 µg/mL

Target

Breast Cancer
HS578T
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 11 Activity

Activity

IC50
IC50=11.3 µg/ml
Anticancer
11.3 µg/mL

Target

Breast Cancer
MDA-MB-435
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 12 Activity

Activity

IC50
IC50=10.6 µg/ml
Anticancer
10.6 µg/mL

Target

Breast Cancer
MDA-N
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 13 Activity

Activity

IC50
IC50=12.9 µg/ml
Anticancer
12.9 µg/mL

Target

Breast Cancer
BT-549
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 14 Activity

Activity

IC50
IC50=23.9 µg/ml
Anticancer
23.9 µg/mL

Target

Breast Cancer
T-47D
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 15 Activity

Activity

IC50
IC50=11.7 µg/ml
Anticancer
11.7 µg/mL

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 16 Activity

Activity

IC50
IC50=12.1 µg/ml
Anticancer
12.1 µg/mL

Target

Lung Cancer
EKVX
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 17 Activity

Activity

IC50
IC50=12.6 µg/ml
Anticancer
12.6 µg/mL

Target

Lung Cancer
HOP-62
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 18 Activity

Activity

IC50
IC50=7.2 µg/ml
Anticancer
7.2 µg/mL

Target

Lung Cancer
HOP-92
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 19 Activity

Activity

IC50
IC50=13.3 µg/ml
Anticancer
13.3 µg/mL

Target

Lung Cancer
NCI-H226
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 20 Activity

Activity

IC50
IC50=10.8 µg/ml
Anticancer
10.8 µg/mL

Target

Lung Cancer
NCI-H23
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 21 Activity

Activity

IC50
IC50=10.7 µg/ml
Anticancer
10.7 µg/mL

Target

Lung Cancer
NCI-H322M
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 22 Activity

Activity

IC50
IC50=12.1 µg/ml
Anticancer
12.1 µg/mL

Target

Lung Cancer
NCI-H460
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 23 Activity

Activity

IC50
IC50=11.2 µg/ml
Anticancer
11.2 µg/mL

Target

Lung Cancer
NCI-H522
Lung

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 24 Activity

Activity

IC50
IC50=12.4 µg/ml
Anticancer
12.4 µg/mL

Target

Brain Tumor
SF-268
Brain

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 25 Activity

Activity

IC50
IC50=12.9 µg/ml
Anticancer
12.9 µg/mL

Target

Brain Tumor
SF-295
Brain

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 26 Activity

Activity

IC50
IC50=9.5 µg/ml
Anticancer
9.5 µg/mL

Target

Brain Tumor
SF-539
Brain

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 27 Activity

Activity

IC50
IC50=13.8 µg/ml
Anticancer
13.8 µg/mL

Target

Brain Tumor
SNB-19
Brain

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 28 Activity

Activity

IC50
IC50=15.5 µg/ml
Anticancer
15.5 µg/mL

Target

Brain Tumor
SNB-75
Brain

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 29 Activity

Activity

IC50
IC50=10.6 µg/ml
Anticancer
10.6 µg/mL

Target

Brain Tumor
U-251
Brain

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 30 Activity

Activity

IC50
IC50=9.5 µg/ml
Anticancer
9.5 µg/mL

Target

Skin Cancer
LOXIMVI
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 31 Activity

Activity

IC50
IC50=10.9 µg/ml
Anticancer
10.9 µg/mL

Target

Skin Cancer
MALME-3M
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 32 Activity

Activity

IC50
IC50=15.1 µg/ml
Anticancer
15.1 µg/mL

Target

Skin Cancer
M14
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 33 Activity

Activity

IC50
IC50=11.1 µg/ml
Anticancer
11.1 µg/mL

Target

Skin Cancer
SK-MEL-2
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 34 Activity

Activity

IC50
IC50=8.9 µg/ml
Anticancer
8.9 µg/mL

Target

Skin Cancer
SK-MEL-5
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 35 Activity

Activity

IC50
IC50=12.5 µg/ml
Anticancer
12.5 µg/mL

Target

Skin Cancer
UACC-257
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 36 Activity

Activity

IC50
IC50=10.6 µg/ml
Anticancer
10.6 µg/mL

Target

Skin Cancer
UACC-62
Skin

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 37 Activity

Activity

IC50
IC50=12.2 µg/ml
Anticancer
12.2 µg/mL

Target

Renal Cancer
786-0
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 38 Activity

Activity

IC50
IC50=10 µg/ml
Anticancer
10 µg/mL

Target

Renal Cancer
A-498
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 39 Activity

Activity

IC50
IC50=12 µg/ml
Anticancer
12 µg/mL

Target

Renal Cancer
ACHN
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 40 Activity

Activity

IC50
IC50=14.1 µg/ml
Anticancer
14.1 µg/mL

Target

Renal Cancer
CAKI-1
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 41 Activity

Activity

IC50
IC50=11 µg/ml
Anticancer
11 µg/mL

Target

Renal Cancer
RFX393
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 42 Activity

Activity

IC50
IC50=11.4 µg/ml
Anticancer
11.4 µg/mL

Target

Renal Cancer
SN-12C
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 43 Activity

Activity

IC50
IC50=13.1 µg/ml
Anticancer
13.1 µg/mL

Target

Renal Cancer
TK-10
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 44 Activity

Activity

IC50
IC50=10.6 µg/ml
Anticancer
10.6 µg/mL

Target

Renal Cancer
UO-31
Renal

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 45 Activity

Activity

IC50
IC50=9 µg/ml
Anticancer
9 µg/mL

Target

Ovarian Cancer
IGROV1
Ovary

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 46 Activity

Activity

IC50
IC50=15.2 µg/ml
Anticancer
15.2 µg/mL

Target

Ovarian Cancer
OVRCAR-3
Ovary

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 47 Activity

Activity

IC50
IC50=17.6 µg/ml
Anticancer
17.6 µg/mL

Target

Ovarian Cancer
OVRCAR-4
Ovary

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 48 Activity

Activity

IC50
IC50=13.8 µg/ml
Anticancer
13.8 µg/mL

Target

Ovarian Cancer
OVRCAR-5
Ovary

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 49 Activity

Activity

IC50
IC50=13 µg/ml
Anticancer
13 µg/mL

Target

Ovarian Cancer
OVRCAR-8
Ovary

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 50 Activity

Activity

IC50
IC50=12.6 µg/ml
Anticancer
12.6 µg/mL

Target

Ovarian Cancer
SK-OV-3
Ovary

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 51 Activity

Activity

IC50
IC50=11.2 µg/ml
Anticancer
11.2 µg/mL

Target

Colon Cancer
COLO-205
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 52 Activity

Activity

IC50
IC50=14.6 µg/ml
Anticancer
14.6 µg/mL

Target

Colon Cancer
HCT-116
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 53 Activity

Activity

IC50
IC50=13.2 µg/ml
Anticancer
13.2 µg/mL

Target

Colon Cancer
HCT-15
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 54 Activity

Activity

IC50
IC50=17.6 µg/ml
Anticancer
17.6 µg/mL

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 55 Activity

Activity

IC50
IC50=12 µg/ml
Anticancer
12 µg/mL

Target

Colon Cancer
KM12
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 56 Activity

Activity

IC50
IC50=12.7 µg/ml
Anticancer
12.7 µg/mL

Target

Colon Cancer
SW-620
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 57 Activity

Activity

IC50
IC50=12 µg/ml
Anticancer
12 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 58 Activity

Activity

IC50
IC50=15.3 µg/ml
Anticancer
15.3 µg/mL

Target

Prostate Cancer
DU-145
Prostate

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2008
Evidence 59 Activity

Activity

0% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Mechanism of action and specificity of antimicrobial peptides designed based on buforin IIb | Peptides | 2012
Evidence 60 Activity

Activity

34% Hemolysis
Toxicity
200 µM
Hemolytic Cytotoxic
34% Hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. | PLoS One | 2013
Evidence 61 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis